ResMed is forecast to grow earnings and revenue by 8.5% and 7.1% per annum respectively. EPS is expected to grow by 8.9% per annum. Return on equity is forecast to be 23.8% in 3 years.
Key information
8.5%
Earnings growth rate
8.90%
EPS growth rate
Medical Equipment earnings growth
13.7%
Revenue growth rate
7.1%
Future return on equity
23.80%
Analyst coverage
Good
Last updated
17 Jun 2026
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
BIT:1RMD - Analysts future estimates and past financials data (USD Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
6/30/2028
6,519
1,852
1,790
1,993
14
6/30/2027
6,096
1,701
1,685
1,832
14
6/30/2026
5,651
1,549
1,616
1,756
14
3/31/2026
5,538
1,520
1,736
1,890
N/A
12/31/2025
5,398
1,486
1,777
1,914
N/A
9/30/2025
5,257
1,438
1,757
1,883
N/A
6/30/2025
5,146
1,401
1,651
1,752
N/A
3/31/2025
5,022
1,313
1,560
1,653
N/A
12/31/2024
4,927
1,249
1,384
1,476
N/A
9/30/2024
4,807
1,113
1,347
1,441
N/A
6/30/2024
4,685
1,021
1,286
1,401
N/A
3/31/2024
4,584
958
1,071
1,199
N/A
12/31/2023
4,504
890
944
1,079
N/A
9/30/2023
4,375
907
792
935
N/A
6/30/2023
4,223
898
559
693
N/A
3/31/2023
4,016
863
408
535
N/A
12/31/2022
3,763
809
222
370
N/A
9/30/2022
3,624
786
305
461
N/A
6/30/2022
3,578
779
195
351
N/A
3/31/2022
3,539
779
344
498
N/A
12/31/2021
3,444
522
446
577
N/A
9/30/2021
3,349
500
397
527
N/A
6/30/2021
3,197
475
620
737
N/A
3/31/2021
3,091
457
733
840
N/A
12/31/2020
3,092
699
774
884
N/A
9/30/2020
3,028
680
684
784
N/A
6/30/2020
2,957
622
696
802
N/A
3/31/2020
2,892
513
505
614
N/A
12/31/2019
2,784
455
N/A
514
N/A
9/30/2019
2,699
419
N/A
573
N/A
6/30/2019
2,607
405
N/A
459
N/A
3/31/2019
2,525
446
N/A
447
N/A
12/31/2018
2,455
450
N/A
456
N/A
9/30/2018
2,405
335
N/A
459
N/A
6/30/2018
2,340
316
N/A
505
N/A
3/31/2018
2,273
307
N/A
516
N/A
12/31/2017
2,196
285
N/A
434
N/A
9/30/2017
2,125
352
N/A
422
N/A
6/30/2017
2,067
342
N/A
414
N/A
3/31/2017
2,029
324
N/A
417
N/A
12/31/2016
1,968
327
N/A
474
N/A
9/30/2016
1,893
346
N/A
510
N/A
6/30/2016
1,839
352
N/A
548
N/A
3/31/2016
1,773
357
N/A
505
N/A
12/31/2015
1,742
357
N/A
471
N/A
9/30/2015
1,710
353
N/A
421
N/A
6/30/2015
1,679
353
N/A
383
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1RMD's forecast earnings growth (8.5% per year) is above the savings rate (3.3%).
Earnings vs Market: 1RMD's earnings (8.5% per year) are forecast to grow slower than the Italian market (11.2% per year).
High Growth Earnings: 1RMD's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1RMD's revenue (7.1% per year) is forecast to grow faster than the Italian market (5.9% per year).
High Growth Revenue: 1RMD's revenue (7.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1RMD's Return on Equity is forecast to be high in 3 years time (23.8%)
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/17 15:20
End of Day Share Price
2026/06/17 00:00
Earnings
2026/03/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ResMed Inc. is covered by 47 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.